Buying Platforms, Selling Pipelines: Deconstructing the Innovation Logic of SINO BIOPHARM
Wallstreetcn·
- China Biologic Products (01177.HK) reported a 2025 total revenue of 31.83 billion CNY, a year-on-year increase of 10.3%, with adjusted net profit rising 31.4% to 4.54 billion CNY.
- The company has undertaken significant acquisitions, including a $950 million purchase of Auron Biopharma and a $1.2 billion acquisition of Hegia, positioning itself uniquely in the domestic pharmaceutical market.
- With a target of launching nearly 20 innovative products by 2028, including advancements in oncology and chronic disease treatment, China Biologic aims for substantial international revenue growth through a dual strategy of acquisitions and global business development.